Trial reportJournal of Korean medical science2020
Comparison of 7- and 14-Day Eradication Therapy for
Trial report in Journal of Korean medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02487511 (Comparison of the Eradication Rate Between 1- and 2-Week PPI Containing Therapies for Helicobacter Pylori Eradication), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Eradication Rate Between 1- and 2-Week PPI Containing Therapies for Helicobacter Pylori Eradication
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Comparing potassium-competitive acid blocker-based therapies forFrontiers in physiology · 2026Pooled it
- Guideline
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-ResistantGut and liver · 2024Trial
- Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Anti-Inflammatory and Antibacterial Properties of Curcuma longa Extract Against Helicobacter pylori.Molecular nutrition & food research · 2025Article
- Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility ofGut and liver · 2023Article
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection.The Korean journal of internal medicine · 2023Article
- [Eradication ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- The benefit of the bismuth add-on to the 2-week clarithromycin-based triple regimen for Helicobacter pylori eradication: a propensity score-matched retrospective study.Gut pathogens · 2023Article
- Prediction of the Drug-Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Antibiotic Resistance ofMedicina (Kaunas, Lithuania) · 2022Article
- Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.Digestive diseases and sciences · 2022Article
- The Influence of Past Metronidazole Exposure on the Outcome ofFrontiers in microbiology · 2022Article
- Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.BMC gastroenterology · 2021Article
- Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-LineYonsei medical journal · 2021Article
- Second-Line Bismuth-Containing Quadruple Therapy forJournal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAlthough
methodsThis study was an open-label randomized controlled trial. A total of 369
resultsIn first-line treatment, eradication rate was 78.5% (106/135) and 78.6% (114/143) in the 7-day and 14-day treatment in per-protocol (PP) analysis (
conclusionPPI-based STT for
trial registrationClinicalTrials.gov Identifier: NCT02487511.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.